VaccineSep 23, 2025

Effective mRNA therapy using E7 protein and IL-12 immune signal in mouse models of head and neck cancer

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 7, 2026

Abstract

Immunization with E7 and IL-12 mRNA resulted in a dramatic decrease in tumor size in mice with head and neck cancer.

The incidence of head and neck cancer linked to human papillomavirus has been rising.
The mEER murine model demonstrated low efficacy with E6 and E7 immunotherapy.
Immunization with mRNA vaccines encoding HPV 16 E7 and IL-12 significantly decreased tumor size.
There was a notable increase in the expression of MHC1 on tumor cells after immunization.
No tumors were detected upon re-implantation of mEER cells after immunization.
Local delivery of IL-12 via mRNA showed no toxicity or increased T-cell exhaustion markers.

Simplified

The incidence of head and neck cancer (HNC) caused by human papillomavirus (HPV) has increased over the past several years. The mEER murine model mimicking HNC showed relatively low efficacy following E6 and E7 immunotherapy. Therefore, this study aimed to examine the anti-tumor and anti-metastatic effects of mRNA vaccines encoding HPV 16 E7, Interleukin-12 (IL-12), and Granulocyte-Macrophage colony-stimulating factor (GM-CSF) in mEER tumor-bearing mice. C57BL/6 mice were injected with cultured mEER cells and immunized with mRNA-LNPs encoding HPV16 E7, GM-CSF, and IL-12. Tumor growth was monitored, and immune responses were analyzed using flow cytometry and Enzyme-Linked ImmunoSpot assays. When immunized with both E7 and IL-12 mRNA, the tumor size dramatically decreased regardless of tumor size, while the expression of MHC1 on tumor cells increased significantly. No tumors developed upon mEER cell re-implantation. Local expression of IL-12 via mRNA delivery revealed no evidence of toxicity or reduced T-cell exhaustion markers. Furthermore, mIL-12 immunization with mE7 induces E7-specific memory T cells in lung tissues, suggesting a defense against potential metastasis and recurrence. Immunization with E7 and IL-12 mRNA is a highly effective treatment option for patients with HPV-positive HNC and is potentially applicable to other cancers.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

Effective mRNA therapy using E7 protein and IL-12 immune signal in mouse models of head and neck cancer

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief